News

Activation Capital Announces Plans for Development of Innovation Center – A New Life Sciences Center at Bio+Tech Park

Activation Capital, an innovation ecosystem development organization, announced plans to develop the 102,000-square foot Innovation Center in the Bio+Tech Park in Richmond, Virginia.

The 34-acre Bio+Tech Park is a commercial life sciences hub in downtown Richmond adjacent to the VCU Medical Center at Virginia Commonwealth University, and is home to over 70 companies, research institutes, and state/federal laboratories. Activation Capital recently announced Virginia Gov. Glenn Youngkin awarded Activation Capital a $15 million portion of a total $66.7 million in grant funding for life sciences projects in the Commonwealth of Virginia.

Amy J. Broderick and Kate Hosko of Cushman & Wakefield | Thalhimer, along with David Thomann of Cushman & Wakefield’s Life Science Group in Boston, MA, have been awarded the exclusive leasing representation for the Innovation Center. Planned for delivery in late 2025, the center will feature approximately 35,000+ square feet of trophy class lab and creative office space for a lead tenant. Approximately 45,000 sf will be dedicated to an incubator operated by Activation Capital and will include shared labs, private offices, and community gathering spaces.  The new building will be located at the corner of 8th Street and Jackson Street.

“As part of our strategic plan to create a thriving ecosystem, Activation Capital will build an Innovation Center that anchors downtown Richmond’s innovation hub and serves as a magnet for innovators to build and grow deep tech companies. Once complete, the Innovation Center will catalyze downtown redevelopment around wealth-creating jobs, boost entrepreneurial growth, strengthen the region’s end-to-end pharmaceutical manufacturing cluster, and act as a platform for upskilling community members with STEM programming.,” said Chandra Briggman, President and CEO of Activation Capital

“In addition to their strong commercial real estate brokerage experience and national life science expertise, Cushman & Wakefield | Thalhimer was selected due to their alignment with Activation Capital’s values of agility, collaboration, entrepreneurial thinking, future-focus, impact, and inclusion,” said Kipton Currier, Vice President of Operations at Activation Capital. “The teams selected for the Innovation Center understand our commitment to the community, our excellence in execution focus, and our dedication to creating a nationally renowned life science innovation center for the benefit of future generations.”

Learn more here.

Recent News

12/11/2024

Liquet™ Medical Inc. Receives FDA 510(k) Clearance for the Versus™ Catheter

Liquet Medical Inc., a pioneering medical device company committed to advancing patient care through innovative technologies, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Versus™ Catheter. This innovative medical device is set to enhance the treatment of pulmonary artery blood clots by offering real-time pulmonary artery

12/03/2024

ivWatch Named to Inc.’s 2024 Best in Business List in Health Products Category

ivWatch, LLC, the IV safety company, is proud to announce it has been named to the Inc. 2024 Best in Business list in the Health Products category. Inc.’s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made a profound impact on their industries and on society at large.

12/03/2024

New Report Finds Bioscience Sector Generates Over $3 Trillion for U.S. Economy

The Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry’s economic performance, its impacts, and its geographic footprint. The report, “The U.S. Bioscience Economy: Driving Economic Growth and Opportunity in States and Regions,” analyzes the sector’s economic impact via employment, overall